Robot-assisted laparoscopic prostatectomy (RALP) shows lower prostate cancer-specific mortality at 12 years compared to open radical prostatectomy (ORP).
Adverse intraoperative events, including prolonged operating time and extensive bleeding, are associated with oncological outcomes such as recurrence and mortality.
Known risk factors for recurrence include higher age, Gleason tumor grade, advanced tumor stage, and positive surgical margins; nerve-sparing technique is not linked to recurrence.
Guideline-Based Recommendations
Diagnosis
Use PSA levels, clinical tumor staging, and absence of metastases to select candidates for radical prostatectomy.
Management
Consider robot-assisted laparoscopic prostatectomy to potentially reduce prostate cancer-specific mortality.
Monitor and document intraoperative adverse events systematically to assess impact on oncological outcomes.
Monitoring & Follow-up
Follow patients with PSA measurements postoperatively at 6–12 weeks and regularly thereafter to detect recurrence.
Use clinical record forms and patient questionnaires to track adverse events and functional outcomes.
Risks
Be aware that prolonged operating time and extensive perioperative bleeding are significant adverse events that may affect recurrence and mortality.
Recognize that surgical difficulties may compromise radicality and increase tissue trauma, potentially influencing immunological response.
Patient & Prescribing Data
Men undergoing radical prostatectomy for localized prostate cancer under age 75 with PSA < 20 ng/ml
RALP may offer small benefits in erectile function and lower prostate cancer-specific mortality compared to ORP; adverse events during surgery should be minimized to improve oncological outcomes.
Clinical Best Practices
Select surgical technique based on patient factors and center expertise, with consideration of RALP benefits.
Systematically document intraoperative adverse events using validated clinical record forms completed immediately post-surgery.
Identify and manage preoperative risk factors to reduce likelihood of adverse events during surgery.
Monitor PSA closely postoperatively to detect recurrence early and guide further treatment.
